Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2022
FDA approves Carvykti for advanced multiple myeloma
The FDA approved ciltacabtagene autoleucel (Carvykti) to treat adults with relapsed or refractory multiple myeloma who have received four or more previous lines of therapy, including specified drug classes.
2021
Novadiscovery expands collaboration with Janssen
Novadiscovery announced an expansion of its collaboration with Janssen, applying its JINKO clinical trial simulation platform to expand an existing lung cancer model for Janssen’s market access and global medical affairs strategies.
2021
Catalent and Janssen expand vaccine manufacturing partnership
Catalent announced an expanded partnership with Janssen to increase manufacturing capacity for Janssen's COVID-19 vaccine at Catalent's Anagni, Italy facility, including vial-filling, inspection, labeling, and packaging services. An additional high-speed vial-filling line was expected to be operational in the fourth quarter of 2021.
2020
Janssen and Sema4 collaborate on cancer trial recruitment
Janssen teamed up with Sema4 to use Sema4's genomic testing and data analytics platform to identify patients for Janssen cancer trials.
2020
Johnson & Johnson expands US coronavirus research collaboration
Johnson & Johnson expanded its collaboration with BARDA and the US Department of Health & Human Services to screen existing antiviral molecules for compounds that may work against COVID-19. Janssen will also work with Belgium's Rega Institute for Medical Research as part of the expanded collaboration.